Dual-layer spectral CT fusion imaging for lung biopsies: more accurate targets, diagnostic samplings, and biomarker information?

Marco Curti, Federico Fontana, Filippo Piacentino, Christian Ossola, Andrea Coppola, Giulio Carcano and Massimo Venturini

Abstract

The increasingly widespread use of computed tomography (CT) has increased the number of detected lung lesions, which are then subjected to needle biopsy to obtain histopathological diagnosis. Obtaining high-quality biopsy specimens is fundamental for diagnosis and biomolecular characterisation that guide therapy decision-making. In order to obtain samples with high diagnostic potential, fusion imaging techniques, such as fusion between positron emission tomography and CT, have been introduced to target the biopsy where there more viable neoplastic cells can be sampled. Nowadays, dual-layer spectral CT represents a novel technology enabling an increased tissue characterisation. In particular, Z-effective images, i.e., colour-coded images based on the effective atomic number of tissue components, provide a higher level of discrimination than usual images based on x-ray attenuation in Hounsfield units and offer the potential of a better tissue characterisation. Our hypothesis is based on the future use of data provided by spectral CT, in particular by Z-effective images, as a guide for appropriate biopsy sampling for histopathological and biomolecular characterisation in the era of patient tailored-therapy.

Keywords: Decision making, Biomarkers, Biopsy (needle), Lung neoplasms, Tomography (x-ray computed)

Key points

- Spectral computed tomography (CT) is an innovative diagnostic tool.
- CT-guided lung needle biopsy is a key procedure in the diagnostic and therapeutic pathway.
- Dual-layer spectral CT fusion imaging could improve the quality of the biopsy sample.

Background

In 2020, lung cancer was the second most common tumour and the leading cause of cancer-related deaths in the USA [1]. Mortality remains very high despite the many therapeutic approaches available such as surgery [2], radiotherapy [3], ablation [4], chemotherapy [5], and immunotherapy [6], alone or variously combined with each other. Screening programs have been largely developed worldwide to early diagnose lung cancer and prevent its metastatic spreading [1, 7]. Moreover, in recent years, the increasing use of computed tomography (CT) led to a rise in detection of pulmonary nodules and lung malignancies diagnosis [8]. An accurate evaluation of the patient’s risk factors and the CT characteristics of the nodule is usually performed but biopsy still remains the
standard of care for a certain diagnosis and a subsequent treatment choice [9].

In 2019, The Lung Imaging Reporting and Data System Lung-RADS [10] was updated from 1.0 to 1.1 version, allowing a better standardisation of lung CT reporting and indications for further diagnostic examination or tissue sampling. In the era of targeted therapies, the role of percutaneous biopsy has gained even more a central role beside the initial histopathological diagnosis, especially considering the role of specific biomarkers guiding therapeutical decisions for many solid tumours [11]. This aspect implies a more extensive involvement of radiologists in the context of multidisciplinary discussions and in the planning of clinical-therapeutic pathways.

Percutaneous lung needle biopsy can be guided by different imaging techniques, such as CT [2], fluoroscopy CT [12], cone beam CT [13], positron emission tomography (PET)-CT [14], or ultrasound in case of superficially located lesions [15]. The choice of the imaging technique depends on its availability, lesion type and location, patient’s collaboration, and operator’s preferences [2]. Lung needle biopsy is a well-established procedure [16], but it may be not diagnostic for several reasons: low percentage of tumour cells, high percentage of necrosis or non-target sampling. The diagnostic accuracy is obviously poorer in case of subcentimeter nodules [17].

Nowadays, sophisticated software allowing fusion imaging with different methods (CT, magnetic resonance and PET-CT) have improved diagnostic accuracy [8, 13]. The capability to fuse morphological information obtained with classical radiological methods and metabolic activity provided by nuclear medicine techniques such as PET seems to be advantageous. In particular, the fusion between fluoro-CT (or cone beam CT) and PET-CT images has proven to be very useful in guiding biopsy procedures, increasing their diagnostic accuracy. Indeed, the intensity

**Fig. 1** Percutaneous lung biopsy. a Axial routine diagnostic image in a patient with solid lung lesion at the upper right lobe. b Effective atomic number-based reconstruction at the same level: the lesion is characterised by inhomogeneous intralesional atomic number with a central area showing a reduced atomic number (yellow–red) and a medial eccentric area showing a higher atomic number (light blue, asterisk). c Intraprocedural cone beam computed tomography (CBCT) shows that the needle has been located in the area with the highest atomic number. d Axial routine diagnostic image in a patient with solid lung lesion at the lower left lobe. e Effective atomic number-based reconstruction at the same level: the lesion is characterised by inhomogeneous intralesional atomic number with a central area showing a reduced atomic number (yellow–red) and an external circular area showing a higher atomic number (light blue, asterisk). f Intraprocedural CBCT shows that the needle has been located in the area with the highest atomic number.
of accumulation of the tracer correlates with biological activity, facilitating the identification of the most active tumour regions [8, 13]. PET is an effective, reliable, and highly diagnostic method, but it is still quite expensive and not a widely available imaging method. A prolonged waiting time can be dangerous in fragile patients such as cancer patients, as it may represent a diagnostic delay.

Hypothesis
A new, latest-generation spectral CT system with dual-layer detector was recently installed at our centre (iQon, Philips Healthcare, Best, the Netherlands. This equipment allows to obtain the spectral separation at the level of a dual-layer detector [18], providing images based on iodine density, virtual non-contrast, and effective atomic number (Z) [18]. These applications permit to enhance vascular contrast, to reduce image artifacts, and to evaluate composition of different tissues or lesions using iodine map and Z-effective images [18, 19]. In addition, these applications allow both a possible reduction in radiation dose and amount of contrast agent to be administered [19, 20]. Z-effective images are colour-coded images based on the effective atomic number of the tissue; this information is obtained from the spectral decomposition process into photoelectric and Compton scattering data [19]. The atomic number of a tissue is also correlated by the presence of iodine within it [18].

In our preliminary experience based on a small cohort of patients with lung lesions greater than 3 cm, we have observed an inhomogeneous Z-effective value within the lesion (Fig. 1). To our knowledge, similar data have been never reported. Highly vascularised areas are those with higher Z values after iodinated contrast medium injection. We hypothesise to use Z-effective images as a guide to biopsy large lesions with an inhomogeneous atomic number assuming that poorly vascularised areas are potentially less diagnostic due to necrosis and fibrosis than hypervascular areas. Therefore, future applications would be to fuse Z-effective data with cone beam CT images during the biopsy procedure, to combine the functional information obtained with spectral CT and the biopsy guidance, increasing the diagnostic power of the biopsy.

Summarising, the dual-layer spectral CT system using the Z-effective images as lung biopsy guide might be helpful to provide more diagnostic samplings and biomarkers information in the era of patient-tailored therapy [21, 22]. Obviously, clinical data will be necessary to support this hypothesis.

Abbreviations
CT: Computed tomography; PET: Positron emission tomography.
11. Osmani L, Askin F, Gabrielson E, Li QK (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol 52:103–109. https://doi.org/10.1016/j.semcancer.2017.11.019
12. Okı M, Saka H (2021) Augmented fluoroscopy and cone beam CT-guided needle biopsy using a steerable guiding sheath: a promising approach for peripheral pulmonary lesions. Transl Lung Cancer Res 10:3701–3704. https://doi.org/10.21037/tlcr-21-696
13. Fontana F, Piacentino F, Ierardi AM et al (2021) Comparison between CBCT and fusion PET/CT-CBCT guidance for lung biopsies. Cardiovasc Intervent Radiol 44:73–79. https://doi.org/10.1007/s00270-020-02613-3
14. Cerci JJ, Bogoni M, Cerci RJ et al (2021) PET/CT-guided biopsy of suspected lung lesions requires less rebiopsy than CT-guided biopsy due to inconclusive results. J Nucl Med 62:1057–1061. https://doi.org/10.2967/jnumed.120.252403
15. Mychajlowycz M, Alabousi A, Mironov O (2021) Ultrasound- versus ct-guided subpleural lung and pleural biopsy: an analysis of wait times, procedure time, safety, and diagnostic adequacy. Can Assoc Radiol J 72:883–889. https://doi.org/10.1177/0846537120939073
16. Sarajlic V, Vesnic S, Udovicic-Gagula D, Kuric H, Akhan O (2021) Diagnostic accuracy and complication rates of percutaneous CT-guided coaxial needle biopsy of pulmonary lesions. Diagn Interv Radiol 27:553–557. https://doi.org/10.5152/dir.2021.20844
17. Portela de Oliveira E, Souza CA, Inacio JR et al (2020) Imaging-guided percutaneous biopsy of nodules ≤1 cm: study of diagnostic performance and risk factors associated with biopsy failure. J Thorac Imaging 35:123–128. https://doi.org/10.1097/RTI.0000000000000427
18. Rassouli N, Etesami M, Dhanantwari A, Rajiah P (2017) Detector-based spectral CT with a novel dual-layer technology: principles and applications. Insights Imaging 8:589–598. https://doi.org/10.1007/s13244-017-0571-4
19. Majeed NF, Braschi Amirfarzan M, Wald C, Wortman JR (2021) Spectral detector CT applications in advanced liver imaging. Br J Radiol 94:20201200. https://doi.org/10.1259/bjr.20201200
20. Masuda S, Yamada Y, Minamishima K, Owaki Y, Yamazaki A, Jinzaki M (2022) Impact of noise reduction on radiation dose reduction potential of virtual monochromatic spectral images: Comparison of phantom images with conventional 120 kVp images using deep learning image reconstruction and hybrid iterative reconstruction. Eur J Radiol 149:110198. https://doi.org/10.1016/j.ejrad.2022.110198
21. Stevenson M, Christensen J, Shoemaker D et al (2014) Tumor acquisition for biomarker research in lung cancer. Cancer Invest 32:291–298. https://doi.org/10.3109/07357907.2014.911880
22. Griesinger F, Eberhardt W, Nusch A et al (2021) Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer 152:174–184. https://doi.org/10.1016/j.lungcan.2020.10.012

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

► Convenient online submission
► Rigorous peer review
► Open access: articles freely available online
► High visibility within the field
► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com